R&D and Production of Pharmaceuticals and Parapharmaceuticals
SectorMost major industry classification systems use sources of revenue as their basis for classifying companies into specific sectors, subsectors and industries. In order to group like companies based on their sustainability-related risks and opportunities, SASB created the Sustainable Industry Classification System® (SICS®) and the classification of sectors, subsectors and industries in the SDG Investor Platform is based on SICS.
Biotechnology and Pharmaceuticals
Business Model Description
Invest in R&D and development of pharmaceutical and parapharmaceutical production
Investing in R&D and the production of pharmaceuticals will increase the competitiveness of the health industry and improve equal access to healthcare
Indicative ReturnDescribes the rate of growth an investment is expected to generate within the IOA. The indicative return is identified for the IOA by establishing its Internal Rate of Return (IRR), Return of Investment (ROI) or Gross Profit Margin (GPM).
20% - 25% (in GPM)
Investment TimeframeDescribes the time period in which the IOA will pay-back the invested resources. The estimate is based on asset expected lifetime as the IOA will start generating accumulated positive cash-flows.
Long Term (10+ years)
Market SizeDescribes the value of potential addressable market of the IOA. The market size is identified for the IOA by establishing the value in USD, identifying the Compound Annual Growth Rate (CAGR) or providing a numeric unit critical to the IOA.
> USD 1 billion
Average Ticket Size (USD)Describes the USD amount for a typical investment required in the IOA.
> USD 10 million
Direct ImpactDescribes the primary SDG(s) the IOA addresses.
Indirect ImpactDescribes the secondary SDG(s) the IOA addresses.
- 1) Maxula Bourse. http://www.maxulabourse.com.tn/sites/default/files/note_valeur/FOCUS%20VALEUR%20ADWYA_0.pdf 2) The Republic of Tunisia, 2021. Voluntary National Review 2021. https://sustainabledevelopment.un.org/content/documents/279442021_VNR_Report_Tunisia.pdf 3) WHO, 2018. Tunisia: Health Systems Profile. https://rho.emro.who.int/sites/default/files/Profiles-briefs-files/TUN-Health-System-Profiles-2018.pdf 4) Tunisia Investment Authority. PHARMACEUTICAL SECTOR SECTOR PRESENTATION. https://tia.gov.tn/storage/app/media/ARGUMENTAIRES/TIA_TUNISIA_PHARMA/AG%20PHARMA%20ANG.pdf 5) Shops Plus and Health Finance&Governance, 2018. Trends in Health Financing and the Private Health Sector in the Middle East and North Africa. https://shopsplusproject.org/sites/default/files/resources/Trends%20in%20Health%20Financing%20and%20the%20Private%20Health%20Sector%20in%20the%20Middle%20East%20and%20North%20Africa.pdf 6) Tunisia Investment Authority, 2021. Pilotage des feuilles de route sectorielles, secteur Pharmaceutique. 7) CAE, 2019. http://www.cae.gov.tn/wp-content/uploads/2019/08/Plan-de-relance-V-Finale-12-oct.pdf
- 8) Vision Research Reports, 2021. Tunisia Pharmaceutical Market (By Formulation: Tablets, Capsules, Injectables, Sprays, Suspensions, Powders, Other Formulations) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook 2021 – 2030. https://www.visionresearchreports.com/tunisia-pharmaceutical-market/38350 9) Grand View Research, 2021. Active Pharmaceutical Ingredients Market Size, Share & Trends Analysis Report By Type Of Synthesis (Biotech, Synthetic), By Type Of Manufacturer (Captive, Merchant), By Type, By Application, By Region, And Segment Forecasts, 2021 - 2028. https://www.grandviewresearch.com/industry-analysis/active-pharmaceutical-ingredients-market?utm_source=report_sample&utm_medium=referral&utm_campaign=sampletest_tunisia_pharmaceutical_market&utm_term=active_pharmaceutical_ingredients_market